KemPharm Inc (KMPH) Given Average Recommendation of “Buy” by Brokerages

Shares of KemPharm Inc (NASDAQ:KMPH) have been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $12.00.

A number of equities analysts recently commented on the stock. Zacks Investment Research lowered shares of KemPharm from a “hold” rating to a “sell” rating in a research report on Thursday, May 17th. ValuEngine upgraded shares of KemPharm from a “hold” rating to a “buy” rating in a research report on Thursday, May 17th. Canaccord Genuity set a $11.00 price target on shares of KemPharm and gave the stock a “buy” rating in a research report on Thursday, May 24th. Cowen downgraded shares of KemPharm from an “outperform” rating to a “hold” rating in a research report on Monday, July 9th. Finally, Janney Montgomery Scott began coverage on shares of KemPharm in a research report on Wednesday, May 23rd. They issued a “buy” rating and a $17.00 price target on the stock.

Shares of KemPharm traded up $0.20, hitting $4.80, during trading hours on Tuesday, Marketbeat Ratings reports. 179,760 shares of the company were exchanged, compared to its average volume of 151,664. The company has a debt-to-equity ratio of -1.13, a quick ratio of 2.83 and a current ratio of 2.83. KemPharm has a one year low of $2.45 and a one year high of $8.40. The stock has a market capitalization of $69.48 million, a price-to-earnings ratio of -1.62 and a beta of -0.51.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.31. research analysts forecast that KemPharm will post -3.45 EPS for the current year.

In other KemPharm news, EVP Daniel L. Cohen purchased 7,900 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The stock was bought at an average price of $6.45 per share, with a total value of $50,955.00. Following the completion of the purchase, the executive vice president now directly owns 35,500 shares of the company’s stock, valued at approximately $228,975. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Delaware Street Capital Master purchased 304,283 shares of the company’s stock in a transaction that occurred on Monday, July 30th. The stock was acquired at an average cost of $4.00 per share, with a total value of $1,217,132.00. The disclosure for this purchase can be found here. Insiders bought a total of 312,708 shares of company stock worth $1,271,290 in the last 90 days. Corporate insiders own 25.90% of the company’s stock.

A number of hedge funds have recently made changes to their positions in KMPH. Millennium Management LLC purchased a new stake in shares of KemPharm in the 1st quarter worth $122,000. Spark Investment Management LLC acquired a new stake in shares of KemPharm during the 2nd quarter worth $176,000. Royal Bank of Canada increased its holdings in shares of KemPharm by 1,847.1% during the 1st quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 22,886 shares during the last quarter. Change Path LLC acquired a new stake in shares of KemPharm during the 1st quarter worth $479,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of KemPharm by 15,976.2% during the 1st quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock worth $795,000 after buying an additional 100,011 shares during the last quarter. 36.41% of the stock is owned by institutional investors.

About KemPharm

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.

Featured Article: Marijuana Stocks Future Looks Bright

Analyst Recommendations for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit